Overview of incretin hormones

被引:46
作者
Efendic, S [1 ]
Portwood, N [1 ]
机构
[1] Karolinska Inst, Dept Mol Med, Endocrine & Diabet Unit, Stockholm, Sweden
关键词
incretin hormones; insulin glucagon-like peptide-1 (GLP-1); type; 2; diabetes;
D O I
10.1055/s-2004-826157
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Incretins are hormones released by nutrients from the GI tract. They amplify glucose-induced insulin release. By raising circulating incretin levels, oral glucose provokes a higher insulin response than that resulting from intravenous glucose. The two most important incretin hormones are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). In patients with type 2 diabetes, the incretin effect is decreased, mainly due to loss of the GIP-regulated second phase of insulin secretion, and because of a decreased secretion of GLP-1. In addition to its insulintropic effect, GLP-1 inhibits glucagon release, prolongs gastric emptying, and leads to decreases in body-weight, all of which explain the marked antidiabetogenic effect of this incretin hormone.
引用
收藏
页码:742 / 746
页数:5
相关论文
共 65 条
[1]   Autonomic regulation of islet hormone secretion -: Implications for health and disease [J].
Ahrén, B .
DIABETOLOGIA, 2000, 43 (04) :393-410
[2]   INTERACTION OF GASTRIC-INHIBITORY POLYPEPTIDE (GIP) AND CHOLECYSTOKININ (CCK-8) WITH BASAL AND STIMULATED INSULIN-SECRETION IN MICE [J].
AHREN, B ;
HEDNER, P ;
LUNDQUIST, I .
ACTA ENDOCRINOLOGICA, 1983, 102 (01) :96-102
[3]   EXON DUPLICATION AND DIVERGENCE IN THE HUMAN PREPROGLUCAGON GENE [J].
BELL, GI ;
SANCHEZPESCADOR, R ;
LAYBOURN, PJ ;
NAJARIAN, RC .
NATURE, 1983, 304 (5924) :368-371
[4]  
CREUTZFELDT W, 1983, SCAND J GASTROENTERO, V18, P111
[5]   INCRETIN CONCEPT TODAY [J].
CREUTZFELDT, W .
DIABETOLOGIA, 1979, 16 (02) :75-85
[6]   GASTRIC INHIBITORY POLYPEPTIDE (GIP) IN MATURITY-ONSET DIABETES-MELLITUS [J].
CROCKETT, SE ;
MAZZAFERRI, EL ;
CATALAND, S .
DIABETES, 1976, 25 (10) :931-935
[7]   Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide [J].
Deacon, CF ;
Nauck, MA ;
Meier, J ;
Hücking, K ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3575-3581
[8]   BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].
DEACON, CF ;
NAUCK, MA ;
TOFTNIELSEN, M ;
PRIDAL, L ;
WILLMS, B ;
HOLST, JJ .
DIABETES, 1995, 44 (09) :1126-1131
[9]   Enhancing incretin action for the treatment of type 2 diabetes [J].
Drucker, DJ .
DIABETES CARE, 2003, 26 (10) :2929-2940
[10]  
DUPRE J, 1976, CLIN RES, V24, pA680